More on BioLineRx Q2 results

BioLineRx (BLRX +2.8%) Q2 results (NIS): Revenue: 0; Operating Loss: (16.8M) (-23.6%); Net Loss: (15.6M) (-10.2%); Loss Per Share: (0.069) (-64.3%); Quick Assets: 63.2M (-44.5%); Cash Burn: (41.5M) (-54.2%).

No guidance given.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs